{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:57:13Z","timestamp":1791881833911,"version":"4.3.4"},"reference-count":86,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1ZIABC012057"],"award-info":[{"award-number":["1ZIABC012057"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Patients with nonmetastatic triple-negative breast cancer (TNBC) or HER2+ breast cancer do not currently have tools to predict treatment response or prioritize options prior to therapy initiation. Pathologic complete response (pCR) is a proxy that requires neoadjuvant treatment. BC-SELECT leverages genetic interactions [e.g., synthetic lethality (SL)\/synthetic rescue (SR)] to predict treatment response via pCR from breast cancer gene expression data. BC-SELECT involves (i) \u201cTraining: gene-pair identification\u201d that identifies clinically relevant partner genes from large-scale datasets for a given targeted therapy or immunotherapy target and (ii) \u201cTraining: parameter tuning\u201d using clinical trials to predict treatment response. We evaluated BC-SELECT\u2019s ability to predict pCR for trastuzumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy, with tuning supported by three trials (n = 86) and validation on nine unseen trials (n = 722). BC-SELECT significantly predicted pCR in 6 of 9 trials, including all PARP inhibitors [ROC-AUCs, 0.6\u20130.8; odds ratio (OR), 1.9\u20133.5] and immunotherapy (ROC-AUCs, 0.7\u20130.8; OR, 3.2\u20137.1). BC-SELECT significantly distinguished between pCR and residual disease in 8 of 9 trials. No current standard-of-care, pretreatment approaches predict benefit in nonmetastatic TNBC and HER2+ breast cancer. BC-SELECT leverages genetic interactions to predict treatment response from gene expression data. Our findings support development of BC-SELECT toward studying how to prioritize PARP inhibitors and immunotherapy in nonmetastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>BC-SELECT is an algorithm that uses gene expression to predict pCR in breast cancer using targeted therapy and immunotherapy. BC-SELECT predicted response to PARP inhibitors and immunotherapy, distinguished responders and nonresponders, and identified different response patterns among tumors with low BRCA1\/2 gene expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0401","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:06:14Z","timestamp":1788473174000},"page":"2382-2394","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transcriptome-Based Synthetic Lethality Predictions to Improve Targeted Therapy\/Immunotherapy Treatment Prioritization in Nonmetastatic Breast Cancer: BC-SELECT"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7509-608X","authenticated-orcid":false,"given":"Yewon","family":"Kim","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Cancer Data Science Laboratory, Center for Cancer Research, , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5087-6674","authenticated-orcid":false,"given":"Matthew","family":"Nagy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00dvg7y05","id-type":"ROR","asserted-by":"publisher"}],"name":"Boston Children\u2019s Hospital 2 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-7425","authenticated-orcid":false,"given":"Rebecca D.","family":"Pollard","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Cancer Data Science Laboratory, Center for Cancer Research, , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-0819","authenticated-orcid":false,"given":"Padma Sheila","family":"Rajagopal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Cancer Data Science Laboratory, Center for Cancer Research, , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 3 Women\u2019s Malignancies Branch, Center for Cancer Research, , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026101304435296500_bib1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","article-title":"Practical implications of gene-expression-based assays for breast oncologists","volume":"9","author":"Prat","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101304435296500_bib2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026101304435296500_bib6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1471-2407-14-177","article-title":"Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens","volume":"14","author":"Nielsen","year":"2014","journal-title":"BMC Cancer"},{"key":"2026101304435296500_bib7","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"2026101304435296500_bib8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamaoncol.2024.3044","article-title":"Breast cancer index in premenopausal women with early-stage hormone receptor-positive breast cancer","volume":"10","author":"O\u2019Regan","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026101304435296500_bib9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/1078-0432.CCR-23-4020","article-title":"Gene expression assays to tailor adjuvant endocrine therapy for HR+\/HER2\u2212 breast cancer","volume":"30","author":"Bottosso","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026101304435296500_bib10","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026101304435296500_bib13","doi-asserted-by":"publisher","first-page":"103220","DOI":"10.1016\/j.esmoop.2024.103220","article-title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: patient-reported outcomes from KEYLYNK-009","volume":"9","author":"Cussac","year":"2024","journal-title":"ESMO Open"},{"key":"2026101304435296500_bib14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamaoncol.2022.4591","article-title":"Combining PARP inhibitor with immunotherapy-does the promise of preclinical data translate to clinic?","volume":"9","author":"Thawani","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026101304435296500_bib15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026101304435296500_bib16","article-title":"Maintenance pembrolizumab\/olaparib misses survival end points in locally advanced or metastatic TNBC","author":"Mauro","year":"2023"},{"key":"2026101304435296500_bib17","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat Commun"},{"key":"2026101304435296500_bib18","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1158\/0008-5472.CAN-16-3478","article-title":"Immune gene expression is associated with genomic aberrations in breast cancer","volume":"77","author":"Safonov","year":"2017","journal-title":"Cancer Res"},{"key":"2026101304435296500_bib19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","article-title":"Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials","volume":"9","author":"Fernandez-Martinez","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026101304435296500_bib20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"key":"2026101304435296500_bib21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13058-023-01743-z","article-title":"Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer","volume":"25","author":"Verschoor","year":"2023","journal-title":"Breast Cancer Res"},{"key":"2026101304435296500_bib22","article-title":"Digital and computational pathology tool harmonization PATH project session 1 presentation. Digital PATH Project Working Group","author":"Stewart","year":"2025","journal-title":"Friends of Cancer Research"},{"key":"2026101304435296500_bib23","article-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) breast cancer","author":"National Comprehensive Cancer Network","year":"2026"},{"issue":"9_Supplement","key":"2026101304435296500_bib24","doi-asserted-by":"publisher","first-page":"GS03-09","DOI":"10.1158\/1538-7445.SABCS23-GS03-09","article-title":"Abstract GS03-09: characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers","volume":"84","author":"Priedigkeit","year":"2024","journal-title":"Cancer Res"},{"key":"2026101304435296500_bib25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101304435296500_bib26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O\u2019Neil","year":"2017","journal-title":"Nat Rev Genet"},{"key":"2026101304435296500_bib27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101304435296500_bib28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"2026101304435296500_bib29","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.1073\/pnas.1508573112","article-title":"Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival","volume":"112","author":"Megchelenbrink","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101304435296500_bib30","doi-asserted-by":"publisher","first-page":"e8323","DOI":"10.15252\/msb.20188323","article-title":"Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy","volume":"15","author":"Sahu","year":"2019","journal-title":"Mol Syst Biol"},{"key":"2026101304435296500_bib31","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","article-title":"Synthetic lethality-mediated precision oncology via the tumor transcriptome","volume":"184","author":"Lee","year":"2021","journal-title":"Cell"},{"key":"2026101304435296500_bib32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.medj.2022.11.001","article-title":"Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome","volume":"4","author":"Dinstag","year":"2023","journal-title":"Med"},{"key":"2026101304435296500_bib33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat Genet"},{"key":"2026101304435296500_bib34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"2026101304435296500_bib35","doi-asserted-by":"publisher","first-page":"PO.17.00135","DOI":"10.1200\/PO.17.00135","article-title":"Clinical value of RNA sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden Cancerome Analysis Network-Breast initiative","volume":"2","author":"Brueffer","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026101304435296500_bib36","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026101304435296500_bib37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/2159-8290.CD-16-0154","article-title":"Genomic copy number dictates a gene-independent cell response to CRISPR\/Cas9 targeting","volume":"6","author":"Aguirre","year":"2016","journal-title":"Cancer Discov"},{"key":"2026101304435296500_bib38","doi-asserted-by":"publisher","first-page":"12372","DOI":"10.1073\/pnas.1109363108","article-title":"Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer","volume":"108","author":"Cheung","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101304435296500_bib39","doi-asserted-by":"publisher","first-page":"140035","DOI":"10.1038\/sdata.2014.35","article-title":"Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies","volume":"1","author":"Cowley","year":"2014","journal-title":"Sci Data"},{"key":"2026101304435296500_bib40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1158\/2159-8290.CD-11-0224","article-title":"Essential gene profiles in breast, pancreatic, and ovarian cancer cells","volume":"2","author":"Marcotte","year":"2012","journal-title":"Cancer Discov"},{"key":"2026101304435296500_bib41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"key":"2026101304435296500_bib42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2026101304435296500_bib43","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2026101304435296500_bib44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"2026101304435296500_bib45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2026101304435296500_bib46","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41467-018-04647-1","article-title":"Harnessing synthetic lethality to predict the response to cancer treatment","volume":"9","author":"Lee","year":"2018","journal-title":"Nat Commun"},{"key":"2026101304435296500_bib47","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/msb.2013.50","article-title":"Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling","volume":"9","author":"Tabach","year":"2013","journal-title":"Mol Syst Biol"},{"key":"2026101304435296500_bib48","doi-asserted-by":"publisher","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026101304435296500_bib49","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2015-0138","article-title":"Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer","volume":"20","author":"Guarneri","year":"2015","journal-title":"Oncologist"},{"key":"2026101304435296500_bib50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41523-022-00427-9","article-title":"Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment na\u00efve gBRCA+ breast cancers","volume":"8","author":"Liu","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026101304435296500_bib51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41523-021-00219-7","article-title":"Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer","volume":"7","author":"Foldi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026101304435296500_bib52","article-title":"nCounter breast cancer 360","author":"Bruker Spatial Biology","year":"2024"},{"key":"2026101304435296500_bib53","article-title":"PanCancer immune profiling","author":"Bruker Spatial Biology","year":"2024"},{"key":"2026101304435296500_bib54","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026101304435296500_bib55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-13-0239","article-title":"Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study","volume":"20","author":"Prat","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026101304435296500_bib56","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1073\/pnas.1201105109","article-title":"Seventeen-gene signature from enriched Her2\/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER\u03b1- breast cancer","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101304435296500_bib57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1755-8794-5-51","article-title":"Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial","volume":"5","author":"Shen","year":"2012","journal-title":"BMC Med Genomics"},{"key":"2026101304435296500_bib58","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"2026101304435296500_bib59","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026101304435296500_bib60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"2026101304435296500_bib61","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/1078-0432.CCR-25-1818","article-title":"KEYLYNK-009: pembrolizumab plus olaparib in locally recurrent inoperable or metastatic triple-negative breast cancer after clinical benefit from first-line pembrolizumab plus chemotherapy","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026101304435296500_bib62","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41586-026-10197-0","article-title":"Homologous recombination deficiency and hemizygosity drive resistance in breast cancer","volume":"652","author":"Safonov","year":"2026","journal-title":"Nature"},{"key":"2026101304435296500_bib63","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3390\/cells12202457","article-title":"CEP55 as a promising immune intervention marker to regulate tumor progression: a pan-cancer analysis with experimental verification","volume":"12","author":"Wang","year":"2023","journal-title":"Cells"},{"key":"2026101304435296500_bib64","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1535-7163.MCT-17-1084","article-title":"Synthetic lethal strategy identifies a potent and selective TTK and CLK1\/2 inhibitor for treatment of triple-negative breast cancer with a compromised G1-S checkpoint","volume":"17","author":"Zhu","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026101304435296500_bib65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2159-8290.CD-14-0552","article-title":"Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map","volume":"5","author":"Martins","year":"2015","journal-title":"Cancer Discov"},{"key":"2026101304435296500_bib66","doi-asserted-by":"publisher","first-page":"v583","DOI":"10.1093\/annonc\/mdx390.033","article-title":"Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer","volume":"28","author":"Sinha","year":"2017","journal-title":"Ann Oncol"},{"key":"2026101304435296500_bib67","doi-asserted-by":"publisher","first-page":"13155","DOI":"10.1002\/cam4.6000","article-title":"LAG-3 transcriptomic expression patterns across malignancies: implications for precision immunotherapeutics","volume":"12","author":"Adashek","year":"2023","journal-title":"Cancer Med"},{"key":"2026101304435296500_bib68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2014potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026101304435296500_bib69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","article-title":"STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer","volume":"8","author":"Pantelidou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026101304435296500_bib70","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026101304435296500_bib71","doi-asserted-by":"publisher","first-page":"eadl2804","DOI":"10.1126\/sciadv.adl2804","article-title":"EZH2 directly methylates PARP1 and regulates its activity in cancer","volume":"10","author":"Meng","year":"2024","journal-title":"Sci Adv"},{"key":"2026101304435296500_bib72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41420-025-02306-1","article-title":"PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells","volume":"11","author":"Yano","year":"2025","journal-title":"Cell Death Discov"},{"issue":"13_Supplement","key":"2026101304435296500_bib73","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1158\/1538-7445.AM2018-1943","article-title":"Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition","volume":"78","author":"Martin","year":"2018","journal-title":"Cancer Res"},{"key":"2026101304435296500_bib74","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"2026101304435296500_bib75","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol"},{"issue":"16_Supplement","key":"2026101304435296500_bib76","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.1158\/1538-7445.AM2020-6394","article-title":"Abstract 6394: combined FLT3 and PARP inhibition induces synthetic lethality in non-small cell lung cancer cells","volume":"80","author":"Ryu","year":"2020","journal-title":"Cancer Res"},{"key":"2026101304435296500_bib77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41420-022-01103-4","article-title":"PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3\/Survivin pathway","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026101304435296500_bib78","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/ijc.30860","article-title":"Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer","volume":"141","author":"Kritsch","year":"2017","journal-title":"Int J Cancer"},{"key":"2026101304435296500_bib79","doi-asserted-by":"publisher","first-page":"e113190","DOI":"10.15252\/embj.2022113190","article-title":"Unrepaired base excision repair intermediates in template DNA strands trigger replication fork collapse and PARP inhibitor sensitivity","volume":"42","author":"Serrano-Benitez","year":"2023","journal-title":"EMBO J"},{"issue":"16_suppl","key":"2026101304435296500_bib80","doi-asserted-by":"publisher","first-page":"e12598","DOI":"10.1200\/JCO.2022.40.16_suppl.e12598","article-title":"Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: results from the Swedish phase II PREDIX HER2 trial","volume":"40","author":"Zhu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026101304435296500_bib81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-023-01748-8","article-title":"Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women","volume":"26","author":"Zirpoli","year":"2024","journal-title":"Breast Cancer Res"},{"key":"2026101304435296500_bib82","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1016\/S2589-7500(22)00188-1","article-title":"Interpreting area under the receiver operating characteristic curve","volume":"4","author":"de Hond","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2026101304435296500_bib83","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.14694\/EdBook_AM.2015.35.e31","article-title":"Triple-negative breast cancer: molecular subtypes and new targets for therapy","volume":"35","author":"Lehmann","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026101304435296500_bib84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"2026101304435296500_bib85","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"2026101304435296500_bib86","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.medj.2023.12.009","article-title":"A systematic analysis of the landscape of synthetic lethality-driven precision oncology","volume":"5","author":"Sch\u00e4ffer","year":"2024","journal-title":"Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0401\/3827155\/crc-26-0401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2382\/3838584\/crc-26-0401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2382\/3838584\/crc-26-0401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:44:02Z","timestamp":1791881042000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2382\/789382\/Transcriptome-Based-Synthetic-Lethality"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0401","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}